NuCana (NCNA) Accumulated Expenses (2016 - 2025)
NuCana (NCNA) reported Accumulated Expenses of $5.5 million for Q4 2025, down 24.69% on a YoY basis from $7.3 million in Q4 2024, and down 7.36% sequentially from $6.0 million in Q3 2025.
NuCana (NCNA) Accumulated Expenses (2016 - 2025) Analysis & Trends
NuCana (NCNA) has 10 years of Accumulated Expenses data on file, last reported at $5.5 million in Q4 2025.
- For the quarter ending Q4 2025, Accumulated Expenses fell 24.69% year-over-year to $5.5 million; the trailing twelve-month figure through Dec 2025 stood at $5.5 million (down 24.69% YoY), and the FY2025 full-year result was $5.5 million, down 25.05% from the prior year.
- Accumulated Expenses slipped to $5.5 million in Q4 2025, from $6.0 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $12.8 million in Q4 2021 to a low of $5.5 million in Q4 2025.
- A 5-year average of $9.1 million and a median of $9.1 million in 2022 frame the typical range for Accumulated Expenses.
- Across the five-year window, Accumulated Expenses soared 84.73% in 2021 and sank 48.19% in 2025, its largest moves.
- Tracing NCNA's Accumulated Expenses over 5 years: stood at $12.8 million in 2021, then decreased by 8.49% to $11.7 million in 2022, then slipped by 5.42% to $11.1 million in 2023, then slumped by 33.9% to $7.3 million in 2024, then retreated by 24.69% to $5.5 million in 2025.
- Business Quant data shows NCNA's Accumulated Expenses at $5.5 million in Q4 2025, $6.0 million in Q3 2025, and $6.3 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.52 Mn |
| Sep 30, 2025 | 5.96 Mn |
| Jun 30, 2025 | 6.32 Mn |
| Mar 31, 2025 | 5.83 Mn |
| Dec 31, 2024 | 7.33 Mn |
| Sep 30, 2024 | 11.31 Mn |
| Jun 30, 2024 | 12.19 Mn |
| Mar 31, 2024 | 10.52 Mn |
| Dec 31, 2023 | 11.10 Mn |
| Sep 30, 2023 | 8.04 Mn |
| Jun 30, 2023 | 6.74 Mn |
| Mar 31, 2023 | 7.81 Mn |
| Dec 31, 2022 | 11.73 Mn |
| Sep 30, 2022 | 11.14 Mn |
| Jun 30, 2022 | 10.08 Mn |
| Mar 31, 2022 | 12.00 Mn |
| Dec 31, 2021 | 12.82 Mn |
| Sep 30, 2021 | 10.77 Mn |
| Jun 30, 2021 | 7.99 Mn |
| Mar 31, 2021 | 7.01 Mn |